SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending as the community discusses the appointment of Kaz Nejatian, former COO of Shopify, as the new CEO, and the return of co-founders Keith Rabois and Eric Wu to the Board.  The news is sparking excitement and speculation about the company's future direction, with many anticipating a potential short squeeze and a shift towards an AI-first real estate platform.  Overall, the leadership changes are seen as a positive catalyst, injecting fresh energy and expertise into the company.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated online discussions, with community members expressing strong opinions and political views. The catalyst appears to be an incident involving political violence, sparking debates about freedom of speech, gun control, and the current political climate. The conversation also touches on broader themes, including social division, extremist ideologies, and the role of political leaders in shaping public discourse.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid reports of a shooting involving conservative figure Charlie Kirk, sparking heated debate and political commentary within the community. Discussions range from the implications of political violence to gun control and broader societal divisions. The incident occurs ahead of CPI data, adding another layer of uncertainty to the market's direction.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to a recently filed $300M mixed securities shelf, leading to community debate about potential dilution and the company's financial strategy. Some investors express concern over increasing expenses and the need for funding, while others believe the shelf registration is a strategic move to capitalize on market movements. Amidst the uncertainty, there's discussion around upcoming FDA meeting minutes and their potential impact on the company's regulatory path for its lead drug candidate.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending due to increased investor attention and a recent company presentation, with the community highlighting its potential for growth within the AI-driven e-commerce sector. Discussions revolve around the company's strong fundamentals, potential for a valuation re-rate, and comparisons to other AI stocks like PLTR. Some traders are also pointing to potentially significant gains pending the upcoming earnings release.

Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.

Wearable Devices Ltd

WLDS is trending due to a recently granted patent for voice and gesture control technology, sparking discussions about potential acquisitions from major tech players like Apple and Meta. Community members are actively debating the stock's valuation, potential buyout prices, and likelihood of a short squeeze, while also weighing the risks of dilution and historical stock behavior. The stock's low float and high volatility are contributing to the intense interest and trading activity.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending amid discussions about a recent offering and its potential impact on investors, with some fearing dilution while others speculate about acquisitions. Community members are debating the company's cash position and the implications for future growth, including possible deals or expansion into new markets. Some are also following developments of the Solana meme coin $KIRK.X

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight bullish chart patterns and strong accumulation, anticipating a potential breakout soon. The community emphasizes the growing strength and organic engagement around the project. Some users are drawing comparisons to Shiba Inu, noting potential connections.

Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. It also focuses on low waste, and ultra-low waste syringe technologies that incorporate both passive and active safety features. The company was founded by Alan R. Blackman and Barry B. Berler on December 16, 2017 and is headquartered in Melville, NY.

Sharps Technology Inc

STSS is trending due to a recent partnership with Pudgy Penguins to expand its Solana digital asset treasury exposure, sparking community discussions around valuation and potential short squeezes. The stock's low float and high short interest are fueling speculation about significant price movement, with community members actively mapping out potential short versus long battle zones. Community members are closely watching the company's ties to Solana and speculating on future price targets.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amid discussions about interest rate cuts, inflation data, and upcoming economic reports, with some analysts anticipating a potential market correction. Community members are closely watching key economic indicators this week for signals on the Federal Reserve's next moves, while also debating the impact of AI and tariff policies on the broader market and specific sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cyclacel Pharmaceuticals, Inc. (CYCC) has been in a downward spiral in 2025, with its stock plunging over 94% year-to-date and more than 76% even after it regained Nasdaq compliance earlier this month.The clinical-stage biotech firm, based in Berkeley Heights, New Jersey, focuses on cancer treatments targeting cell cycle, transcriptional regulation, epigenetics, and mitosis. However, its lead candidates—fadraciclib (a CDK2/9 inhibitor) and plogosertib (a PLK1 inhibitor)—have failed to inspire investor confidence.The trouble began in October 2024, when initial Phase 2 data from a trial of fadraciclib in solid tumors showed only two patients with stable disease among six efficacy-evaluable participants.Research firm Roth MKM called the results “not encouraging,” especially given the patients' favorable genetics, adding that Cyclacel required three or more patient responses to justify continued development.That triggered a sharp fall in <a href="https://stocktwits.com/symbol/CYCC">Cyclacel shares</a>. Struggling to stay afloat, the company then turned to investor David Lazar in January for a $3.1 million funding deal, which included leadership shuffling. Lazar was named interim CEO, replacing longtime chief Spiro Rombotis, and several board members stepped down.In March, Cyclacel raised another $1 million through a private placement of convertible preferred stock.&nbsp;Two months later, Cyclacel pivoted sharply, announcing plans to acquire Fitters Sdn. Bhd., a Malaysian firm focused on fire safety and waste-to-resource solutions. The deal, structured as a share exchange with FITTERS Diversified Bhd., will give the parent company nearly 20% of Cyclacel’s stock. Cyclacel shareholders will retain 80%, and the company said it would rebrand as Bio Green Med Solution, Inc., with a new ticker on the Nasdaq.The merger still requires shareholder approval and must close by Aug. 31.Retail sentiment for CYCC has turned increasingly ‘bearish’ over this period, accompanied by a fourfold jump in message volume over the past month.The company’s rebranding and Nasdaq compliance milestone have failed to stem the stock’s decline, indicating investor skepticism about the firm’s future direction.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Cyclacel Stock Tumbles Over 76% Since Regaining Nasdaq Compliance: What’s Ailing the Nanocap Biopharma Firm?

The company’s rebranding and leadership shuffle have failed to stem the stock’s decline, indicating investor skepticism about its future direction.

Equity

Sangamo Therapeutics, Inc. ($SGMO)Sangamo shares spiked over 30% by the mid-session with sentiment on Stocktwits continuing to remain ‘extremely bullish’ for a second day in running. This marks a turnaround from a week ago when the sentiment score was 35/100.&nbsp;As of 3:05 pm ET, pn Stocktwits the sentiment score was at 97/100. Message volume has improved from ‘normal’ a month ago to ‘extremely high’ this week.&nbsp;On Tuesday, Sangamo announced its successful interaction with the U.S. FDA that provided a clear regulatory pathway to the accelerated approval for ST-920, a wholly-owned gene therapy to treat Fabry disease.&nbsp;The drug regulator agreed in the interaction that the data from the ongoing Phase 1/2 STARR study&nbsp;can serve as the primary basis for approval under the Accelerated Approval Program.&nbsp;“I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated,” said Sandy Macrae, CEO of Sangamo.<figure class="image"><a href="https://stocktwits.com/symbol/SGMO"><img style="aspect-ratio:643/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/sgmo_sentiment_8fa3195ce2.png" alt="sgmo sentiment.png" width="643" height="147"></a><figcaption>&nbsp;SGMO sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The company said it plans to submit the Biologic License Application in 2025.Cyclacel Pharmaceuticals, Inc. ($CYCC)Nano-cap biotech Cyclacel also saw a surge in retail interest. The&nbsp;sentiment meter on Stocktwits&nbsp;was trending in the ‘extremely bullish’ territory, with a score of 96/100 as of 3:05 pm ET. This marked an improvement from the ‘bullish’ predisposition seen on Monday. Message volume has spiked significantly, with the corresponding score improving from 63/100 on Monday to 93/100.<figure class="image"><a href="https://stocktwits.com/symbol/CYCC"><img style="aspect-ratio:627/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/cycc_sentiment_58035ef869.png" alt="cycc-sentiment.png" width="627" height="138"></a><figcaption>CYCC sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The extremely positive stance of retail traders came ahead of the oncology-focused company’s presentation of the initial safety and efficacy data from&nbsp;12 patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent.&nbsp;The data is due to be presented between 6 am ET and1 pm ET on October 23, 2024 at the AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics to be held in Barcelona, Spain.GE Aerospace ($GE)GE Aerospace stock was plunging on Tuesday following the company’s third-quarter results, which showed revenue coming in slightly shy of estimates. The adjusted earnings from continuing operations, however, beat the consensus.Retail investors threw their weight behind the company, with the sentiment score on Stocktwits at 96/100 as of 3:05 pm ET, suggesting ‘extreme bullishness.’ The score is up from 79 a day ago. Message volume has been extremely high, with a score of 96/100, up from 72/100 on Monday.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/GE"><img style="aspect-ratio:667/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ge_sentiment_f01d6d0683.png" alt="ge-sentiment.png" width="667" height="137"></a><figcaption>GE sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 3:05 pm ET, Sangamo was up 35.3% at $1.24, Cyclacel gained 12.55% to $1.49, while GE Aerospace fell 8.84% to $177.05.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/texas-instruments-stock-slips-ahead-of-earnings-retail-sentiment-turns-bullish-amid-rise-in-chatter/cJ2XQFWReS">Texas Instruments Stock Slips Ahead Of Earnings, Retail Sentiment Turns Bullish Amid Rise In Chatter</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon

These 3 stocks are riding on catalysts in Tuesday's session.

3 stocks outperforming the broader market Tuesday

A small-cap biotech and a far smaller nano-cap peer and GE Aerospace were among the stocks retail traders were the most bullish about on Tuesday.


Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Decline in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC  Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 26,600 shares, a drop of 35.9...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a report issued on Tuesday morning.
A number of other brokerages...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by StockNews.com

StockNews.com cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a hold rating to a sell rating in a research report report published on Monday morning. Other analysts have...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation Oral Plogosertib Preclinical Data Support Precision...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a research note released on Thursday morning. Several other...

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel...

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals Inc

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$KLAR IPO day is upon us, how are you playing it?

Stocktwits

Klarna Group plc

 IPO day is upon us, how are you playing it?

CYCC
Cyclacel Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYCC News

CYCC Cyclacel Pharmaceuticals Inc